It was experimentally proven that preventing the development of local insulin resistance by blocking NLRP3 inflammasomes and mediated neuroinflammation should be considered a pathogenetically grounded approach to correcting cognitive disorders in Alzheimer’s disease. Here, NLRP3 is linked to Cognitive impairment.